KURA - Earnings call transcript Q1 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Kura Oncology First Quarter 2019 Financial Results Conference Call. [Operator Instructions] I would now like to introduce your host for today's conference, Mr. Pete De Spain, Kura's Vice President of Investor Relations.

You may begin.

Pete De Spain

Thank you, Sara. to first welcome call. XXXX and afternoon, Kura quarter Oncology's conference Good

Gualberto, Officer me Kura Dr. Chief Chief Officer. President Antonio from the Marc Executive Chief Dr. Dr. Joining Financial call Business our Grasso, are our on Officer Development; Head and of Troy Chief Wilson, Officer; our and Medical and and

statements will that I represent risks current remind you to I the turn like on for to the call factors of as and Oncology. call Before that information are Kura's judgment actual refer from and based today's management's With CEO the over with to include call could today, would available expectations. affect involve expected Please statements to the materially Kura SEC differ SEC, Such I the could Dr. the from on Wilson, Wilson, turn may company. results will forward-looking that now and cause which Troy President of website concerning results. or that, over risk filings Oncology Dr. to Kura uncertainties

Troy Wilson

of an neck RUN-HN patients and which plan head the cell And to trial execution update provide treatment in afternoon. carcinoma. is and our trial And phase HRAS-mutant squamous open-label Meanwhile, year. designed additional to Pete. this least joining half ongoing evaluable in focus two us RUN-HN. track. we at we over XX made on proceeding patients the we've trial quarter considerable all cohort from We second HRAS-mutant progress on that of operational for this our you, thank with the registration-directed continue it's to the The I'm you, initial past Thank pleased of call non-comparative We've tipifarnib. as enrolled of report HNSCC global to enroll

additional carcinoma as on HNSCC ongoing preliminary squamous We cell in follow-up expect in enrolled as trial as cohorts. newly other this the as will patients well data well the on patients include update that both

made registration-directed as study application tipifarnib's our data of with HNSCC to we goal support also targets progress generate CXCLXX-driven marketing include use as potential and a diseases indications. potential tipifarnib the of work identification between development broaden the tumor well linkage soon mechanistic other CXCLXX. protein of package as while is in inhibition as a Our HRAS-mutant farnesylated farnesyltransferase Further We've to solid high unmet need. for possible the in hematologic significant to an supporting toward of and approval to number

Antonio call officer. turn our For medical more to head over this, on I'll Gualberto, chief the development and of

Antonio Gualberto

of of as we solid activity Troy. the multiple as Johnson mechanism HRAS-mutant the had features data provided of when exclusively across hematologic Thank of oncogene. from action tipifarnib strong well the farnesylated licensed in activity, signs in evidence you, activity problem decades. has compelling Despite the elusive generated tumors. certain anti-tumor of remained for Among it we the The indications farnesyltransferase driven of evidence inhibitors tumors were HNSCC upsurge these durable this by

in of angioimmunoblastic results a of factor fact, prognostic an we benefit of form the CXCLXX reported an negative clinical well expression cancer as T-cell of do care from aggressive data PTCL, been myeloid a which T-cell clinical high between a such breast we typically our as stage phase In show Annual Hematology The pancreatic of lymphoma. evidence not time, other association significant many December a therapy. CXCLXX concept expression. tumors same often from CXCLXX levels characterized by standard Meeting, XXXX, data activity two which of reported However, for reported, cancer lymphoma, non-clinical American high as in mutations. study as Society indicated peripheral at ancillary, tipifarnib, of correlate At trial proof expression primary that that lymphomas, leukemia, the PTCL have of and or the later is,

that tipifarnib We well stroma. pathway HRAS-mutant marrow attached now enrich using The biomarker our to that by treatment. preliminary results development can observation of is secretion for tumors tipifarnib and also reported a bone validated patients most regulate CXCLXX beyond of models CXCLXX potential the showed to in CXCLXX target related tipifarnib path of solid from expand provided the likely benefit tipifarnib to a therapeutic

Importantly, certain elevated poor a patients CXCLXX is tumors, metastasis. to and An in including contribute to expression its pancreatic receptors to with factor be are known prognostic CXCLXX cancer. known

the the clinic We biomarkers have An provide the prodding farnesyltransferase provide this Association further CXCLXX for body farnesyl mechanisms CXCLXX the the expression? tipifarnib of phase of observed and expression tumors many gene supporting growing farnesyltransferase previously fact lymphoma These and of stated, such molecular inhibition large question, immediate the refer are well Individual indications. the to market American pathway help the lab are companies of trial connecting patients encouraged of from strongly conducted work in a common as a us previously large associated believe of buyer tipifarnib. the identified mechanistic bone of years. As patients Not that a inhibition expression anti-tumor may with mechanism remains. findings tipifarnib We CXCLXX of X in in for number the political Annual in despite increasingly to inhibition common clinical a with relate across diffuse form and of as such academic fungoides, activity subset with multiple solid believe that investigator, it We activity by defined. benefit data. Cancer the basis with of on most in targeting patients B-cell lymphoma. exclusively to the cutaneous of in in mycosis in sign pharma for analysis CXCLXX the still T-cell Last farnesyltransferase of [indiscernible] the however, tipifarnib benefit outstanding potential CXCLXX of for identify the by been stroma. the the our new as related that What pathway molecular funding hematological a have high the Meeting, expression we clinic lymphoma enrich make reported suggesting month, at CXCLXX pathway a is inhibition from mechanism of findings evidence CXCLXX marrow Research with

birth, Now ongoing elucidate we And from of cohort have continue positive the and to for hematological mutations the be AITL June. accepted this of further tipifarnib, CXCLXX to and to the expression. to providing original at phase been next more Troy. in association. that additional molecular two farnesyltransferase associated cohorts month would our from to we data presentation. with the from including estate expect a And ICML efforts in identification the the data there data say call forward in the that including the trial pleased as we while well. biology With two response our both light tipifarnib PTCL look lymphoma, I all back a turn either PPPCO, now report cohort. malignant original and limited am for potentially At our congress on will over of data conference specific mechanism genetic that, of CXCLXX Meanwhile, of I action international

Troy Wilson

CXCLXX the team expand opportunity by to for be program. Antonia. with cancer. discovery significantly continues to tipifarnib related therapeutic as I of biomarkers development make progress our treatment the tipifarnib the encouraged offers for continue the you, a to with The potential very patients Thank

treatment of that Namely, served has evidence forward CXCLXX CXCLXX-driven patients meantime, a similar schedule, half. HRAS for providing us in strategy the the earlier from an clinical indications by benefit, update dose in with in prioritize patent additional CXCLXX lines strategy approach biomarkers development to tipifarnib prospective next and phase tumors mutant month second hematologic ongoing that would and solid consider our from exclusivity. need. clinical we indications, enrich those for data for biomarkers tipifarnib Ultimately, RUN-HN In followed follows driven which with and potential high, of multiple is of protection and/or the opportunity our move believe enable pathway two for securing regulatory validation an potential registrational unmet development and clinical the to in elements key we tumor strategies there as tipifarnib of to therapy. we durable well look PTCL Our positive benefit, a could for optimizing into trial of of this trial HNSCC. for CXCLXX seek rapid Other include we

turn a potent MAP our is our KO-XXX. emerging selective a molecule Now potential and with pathway. dysregulated kinase attention let's in to programs, quickly pipeline the of KO-XXX activity inhibitor ERK ERK beginning patients treatment inhibitor tumors our advancing have small as with that for we're which

as suggests data or subsets mutant BRAS preclinical has of carcinomas. cell adenocarcinomas well as in KRAS that Our activity squamous anti-tumor certain KO-XXX

for KO-XXX. to evaluate regiments continue We dosing

goal that And providing the dose. is to later a we would reach trial remain We on recommended or year. one tolerated goal to does data phase when track accomplish Our two we believe available. this on phase anticipate a maximum

partial KO-XXX with genes and the MLL in those rearrangements NPMX. oncogenic is duplications third of molecule product MLL protein data the leukemia, or anti-tumor menin-mixed well that Our those generated protein mutations of support tandem genetically KO-XXX, including preclinical We've candidate leukemia inhibitor, small potent as with subsets potential selective as the a lineage in defined activity or such gene acute and driver as interaction. menin

of to now FDA. call relapse that, Our results financial our shortly. investigational for quarter one been new for Marc initiate first to KO-XXX drug a And AML our for preparing refractory we're I'll cleared by in of discussion clinical application has Grasso the trial to phase the over With XXXX. turn

Marc Grasso

$XX.X XX-Q detailed And was brief clinical for Thank $XX.X development expenses review quarter an invite the to of our Research the our increase more activities The tipifarnib, results compared were overview call the to XXXX our two related discussion. in tipifarnib. clinical filed XXXX. quarter registration-directed to million you activities provide and offset trial for you, our quarter decrease to of by million financial in due in a afternoon, phase first I'll for development first today a R&D and of expenses for primarily Troy. trials a decrease on the related good of everyone. to development here for

strengthen the $XX.X regulatory operations for in million affairs. to research quarter XXXX. The of primarily XXXX $XX.X first of first hires to with $X.X the due and expenses million of increase share-based in team development of personnel first $X.X $X.XX the General or We compensation quarter share a areas the continue $X.XX quarter XXXX compared quarter share was XXXX. the were increases compared key of was the of non-cash, loss loss million costs. per net for Net per for to administrative million clinical and or in and and for to first expenses G&A

$XXX of into well-funded remain We As through cash, of compared and XXXX, equivalence, with investments million upcoming XXst, million our operations will and expect cash, as back cash With and $XXX.X XXXX. short-term the March December had current equivalence, short-term that, XXst, Troy. we turn cash of will current I be our to milestones call sufficient over fund XXXX. investments that to now

Troy Wilson

we Marc. prepared lay you, anticipated quickly remarks. let Thank our concludes just before jump me Q&A, near-term into But milestones. out This our

additional trial two PTCL tipifarnib, in and ICML our at CXCLXX EHA data June. For positive from AITL in phase and

at elevated ICML associated biomarkers with on CXCLXX data Additional June. expression EHA and in

from our chronic phase two HNSCC other data two of our in second the trial additional leukemia in half HRAS-mutant trial SCCs and in monocytic Additional from XXXX. phase And myeloid XXXX. HRAS-mutant in data

mid-XXXX. initiation For Operator, one dose trial ready the for now questions. we're of trial in one KO-XXX, that, KO-XXX, our data in XXXX. phase of our phase from second escalation for And half With

Operator

first Jonathan question comes Our STB Chang Leerink. from Instructions] [Operator with

Your line is open. now

Jonathan Chang

all the taking for getting at Thanks EHA guys. and And questions. congrats on ICML. Hi, presentations

investor as more upcoming on follow-up, got would And etc. upcoming the of we we in ahead question, terms you the a PTCL data win patients, you many in benchmarks help will at PTCL? the in see set more ASH? what EHA, expectations to there First can how consider you And do data what the look versus much be data? how as

Troy Wilson

going I'm Antonio questions. ask two to address to your Jonathan. Thanks,

Antonio Gualberto

Yes. Thank you.

So, call. Jonathan, the thank you, for

AITL. the data concept So, proof we indicated ASH that at of presented in

you at the If the time, recall cohorts. enrolling CXCLXX positive we still were

you provide that was the is that that and drive a sufficient the it it first enzyme And they toward [indiscernible]. intention meeting thing to the certainly can getting some from investigators detail, with tell only in I to the our cohort. presentations into is without So,

the field outcome So, was certainly, there of in the wasn't from the in study. data a strong those showing in their that interest

Jonathan Chang

we new Abstract upcoming there be I a guess or much versus placeholder it. will And should the largely for data presentation Got be ASH expected to the presentation? how

Antonio Gualberto

good a is question. that So, actually

intention of So, was I what the And And to you We its be you activity. the if -- what or expecting, saw can the -- tell has addressing on proof your the driven checked histology level that have we concept. data you again, objective. recall, on And we based are based level -- will attempting based of marker. of expecting on It or that presentations. trial I to then our the initial maybe is saw is We reached outcome, basically selection. selection. were question for reach some toward

Troy Wilson

Jonathan, data timing -- But since the has given of just mature the answer those to say then. know your that I question, don't But they're to placeholders. I'd continued abstracts

wouldn't expecting I be June than described a data So, more see in in the what's to set perhaps abstracts. mature

Jonathan Chang

about Got for far color. Where KO-XXX the or dose initial more the it. question. talk are ERK And the current you close are one phase in how the inhibitor from we clinical status one data? optimization Thanks just of seeing Can Maybe you study? process?

Antonio Gualberto

question. good a it's So,

have There programs. a difficult it's abandoned they as So, those that have been orders quite target.

tell So, want sure for What to that have we you the phase that regiment can we confidence a continue I we is is or cohort make the either two. have the one sufficient extension escalating. thing appropriate that to

So, -- there reasons us are there the are escalations. stops in no no for

We to regiment. optimize what is trying are the just best

get end by the is the the suggested by But intent then and select phase to two that the patients goes [indiscernible]. year. recommended of on were the may So, based happen that markers the

Jonathan Chang

Thank very taking questions. much Got you, it. the for

Operator

Chris question Shibutani with comes next from Cowen. Our

line now Your is open.

Chris Shibutani

much. very Thanks Yes.

there's a sense framing the in approaching On I also can inhibitor, preview give menin bit another for you're one the clinical us clinic. of development you there? a that's perhaps believe the how little

keen what the Any could helpful observe be to be insight be. keep strategies we'll tease That to and would be us different think would I engaged differentiation little. so, and And a additional us great.

Antonio Gualberto

Yes.

of be as So, you ahead appear to we know, others.

IND what I shortly. that you're or This that But had was soon how you will question a can don't select And turn has the been variation studies. off, no nature happen an quick is It's molecularly. a factory a etc. FDA. a in there contracts, is But will have intend [indiscernible] that population on on escalation expect one not We have you escalation IND they're just by are cleared some basis. standard dose submitted the paperworks, to the of bringing delays. We tell AML major phase dose differences behind. a if and We're major

where ahead. get those answers Although, will AML don’t and at -- you NPMX-mutant go know to I are question. some for expecting rearrangements we this your population point, look activity. if Well,

Chris Shibutani

that's helpful. no Yes,

kind development the with I folks that's be. there as the potential progressively speak you of we if could terms about And could potential sense realize anticipate that pathway to believe about helpful. contemplate clinical it are And not either think a of for how as pretty about insights logical the there it potential in whether you're what AML think landscape combine development mechanistically the Many in think and of makes and you combination has changed over and with also even early you your past I'm of most a when combinations. the the wondering I a stage drug but there few regions. paradigm to physicians thinking so at that'll set that evolving other of be particularly got agents to combination, is of you if or years

Pete De Spain

good Yes. very It's question. a

reason simple a NPMX back for adult you don’t So, say that population. need to the against the that the your monotherapy on therapies specific not are I turn will they mutated

mutations that vision have mutations you also you example is know. patients have Now, him find TX maybe concurrent may NPMX, our to that through for new and NPMX for and

to should the consider combination, although that as standard-of-care. with combination So, exciting on gives you need not percentage you

recommended to whether therapy get your the will So, may those maybe in co-mutations of NPMX. targeting dose pending to get agents standard-of-care you with phase and it target line I both put the early for you responses, are you within not combination it that or we can want way the appear consider that or

Chris Shibutani

IP HRAS-mutant efforts believe for you have talked think that deck related lastly exclusivity? you your state after the investor the then, think where including you you had the a just that of community that to I and timelines you'd very on patent about some are slide outlined for -- CXCLXX current XXXX Troy IP And Great. in except encouraging is the out those to in could to in terms about go up Thanks, XXXX. that standpoint much. pragmatic terms what of From rough expressing you're of extent

Troy Wilson

Sure, Chris.

that's Europe. the but multiple patent patent an we in been the That step in XXXX potentially you patents of So, now what even we how like optimism. reason that issue are getting how applications look ability throughout. is I been at show a it in maybe the are and will. presentation, the XXXX dosing that taking in just question. are we the U.S. patents to corporate it where never the in and at That’s well U.S. that they're connect And this your biomarkers, patents to I if And development, the the the not as exact There guiding successful theme think I the you under say sort there the table before really a the schedule. back were beginning that disease overlapping longer known. we've pending, the quite inventive at answer in or you have mechanisms we And molecular issued as if only issued is runs brought not think has protection was to imagining step for a drug U.S. outside

this year sort given patent fertile lot and continue and from interesting you'll see into think of throughout that's a to so, year. ground us next I And portfolio of our developments

that as that's out playing along something with strategy much marching development definitely hand-in-hand very successfully. it's is So, the

Chris Shibutani

so guys. you, we Thank to for forward those updates. thanks. Well, mid-summer data certainly Great, look there see

Operator

comes Our Joel next Citi. with question from Beatty

Your open. is line now

Unidentified Analyst

Hi, This for Sean in is Egan guys. calling Joel.

and I for one got then one think for I Troy Antonio.

question. First of a all clarification

the AIM-HN, For study. registrational

a XX reject that to you your just objective know or a happen kind will more enroll data And now, with that for comprehensive I response responses you hit but you'll Or will or means see Antonio, progress to recent of you update to the study then going on target reach If criteria patients an enrollment confirmed pain forthcoming of made continue Is kind how just of is forward. your roll don’t enrichment. out if as study as pain pancreatic and wondering use have rate. you kind BRAFs. to wondering that or you of of in how analysis what'll like to I the objective an be able enough tethering kind I'm leverage your KRAS any

Troy Wilson

Sean, can ASCO and the me to address Antonio your the relating AIM questions. GI. the for thanks take I'll questions then data let around pancreatic questions from your

respect with least study's you're intended to XX So, evaluable patients. AIM-HN, enroll correct, to at the

its the we there and if to and the company However, need proof-of-concept not II very the analogous DSMB hypothesis II endpoint. submission if point with are as the likely the have were would would notify in not would go would that the in agency. the opportunity completion able notify towards XX trial enroll steps that we study. agency Phase expectation that us It the next a meeting in objective be expect situation. It's Phase achieved trial FDA to was met would that a in is a continue patients to HRAS-mutant which the trial confirmed enrollment the end would dialogue study very turn our the much that we've efficacy our enrollment and had and of would primary said with We illuminates null begin complete, trial also of publicly. announce positive the that responses, manner prior give had to but around an to an we At

Antonio Gualberto

GI the you So, ASCO pancreatic for to excitement that the brought investigators. data mean, reference. that thank I presented we some the at

we there with where or be like a suggest earlier the very can setting. further a have expiration was on these metastatic kind of So, balanced But of that's population for And between expiration CXCLXX KRAS. you CXCLXX that could a say connection registration. helpful to good actually analysis that some that and you locally little setting a mostly you potentially now you are potentially path that referring paying a will relationship if recall be on frequency also that the is

more a be a could the line So, medical and potentially molecular second tools. setting, it intent med patients select in our based to is that potentially to on need

or example see X% in XX% big So, patients a and we than can a KRAS is you frequency of chunk little a CXCLXX mainly marker of selection the patient for lower to related on that then population give patients the the you bit that of where benefit. potentially the can better time a apply developed responses are identify you it's when clinical how little better

a with tools have discussion, and proof-of-concept in do with about are intent and to this we we study and we our KOLs is the say pancreatic So, those currently initiate strategy year.

Unidentified Analyst

thank for Great, much questions. taking so you my

Antonio Gualberto

Sure.

Operator

Van Our with Piper comes Tyler question Jaffray. Buren next from

is now Your line open.

Unidentified Analyst

guys, Hi on questions this Tyler. Alex is for Two for you.

your would are you have and significant internal we development secondly, How the target yet. opportunity you for for program partnership? tipifarnib, the recent bearing how given thinking with clinical the And for in on any between or compare in which inhibitor more combination make course that to programs than the sense indications words it data KRAS in don’t would excitement of ERK activity XXX the mind Thanks. to prioritize about First, inhibitor combine you with to outcomes? in improve secondly, be would in agent And clinical ERK and to expect program therapy KRAS other for for other. potential single the addition powerful one or KRAS

Troy Wilson

Sure.

were we about pretty are your respect questions. meaty question lot to indications, talking it's those first prioritization internally. it's on something With great two of a question, a So, that

we're in initially prospectively we're in PTCL, CMML. to way seems now the later shown looks pancreatic, We've at AITL in then CXCLXX And the potentially by in be which DLBCL. prospective think encouraged data validated hypothesis again, year the out. quite AML, and retrospective I that to going playing see,

driving pathway have in CXCLXX disease. common to be that indications those the seems the of All

to things that in that alluded and with trial you success of care to to a smaller to the foothold anchoring be initial to either and standard allows the of you displace this higher want really remarks become the likelihood -- gives -- a is we care. we've standard drive a of focus of to get of prepared able tried the you on that part One or indication

think share I later an see more that that. we're after encouraged the increasingly with we for to have say to a we'll bit And you our we're multiple probably With little able the very, in PTCL opportunities on good update studies, different congress a second it's And as are Antonio agents. in mentioned, and year question, question. at EHA there your very to Lugano. respect two

of And KRAS draw promise window. the data. comparisons, that particularly you as of is the absence so, a in of directly. reasonable you oncoprotein consequence potential have that, for a the GXXC And are The inhibitors, an to it's inhibitors, inhibiting hard the therapeutic

for identify type actor. And other we've populations do a there the about in is ERK that is you you talked and agent pathway. central that One about activity. can We're single a You the wild the But two distinct are chokepoint forward. drive where have meaningful is resistance. past. inhibiting ERK, to it on ways mutations with in hand, protein dysregulations really worry

where The that can you combination. benefit other opportunities identify is clinical you drive in

combine inhibitor small can a opportunity But your is companies more use of to really still would, combine figure different two have Is and as gravitate best do ERK that to agent. you think combination a your monotherapy that those mentioned, agents. a just But number of an what to reasons can dose we to tell, KRAS deploy that that to an optimistic both and recommended can are there's an in you to with best want of opportunity how for as to understand We an it course, Antonio how there that we're far then I toward is inhibitor setting. the ERK Certainly. key And inhibitor? possible. phase out tractably. As single-agent

forefront development. work this step setting as position question of we the one keeping next very So, the to mind we're in out much XXX finish our for and that of phase hopefully

Antonio Gualberto

thing necessarily is only The not will that strategies add are exclusive. mutually I

most a the can tipifarnib be work combination That require on and on trials. randomized you likely could So, pancreatic indication. will

Some that But give can take parallel, you large, large lymphoma B-cell And translate will you opportunity. years. diffuse may several an to a commercial in registration. pursue monotherapy AITL subset it or as

line For one value. it a determines after another have company registration up like us, having

both can do strategies respond. could time you pursue this that you in can the and opportunity anchoring is developing in do the at that you background. parallel commercial you So, that have indications Then also [indiscernible] same label big,

Unidentified Analyst

Great. you. Thank

Operator

with next comes Oppenheimer. from Jay Our Olsen question

is now line Your open.

Jay Olsen

taking transmutant could Oh, if we expect see approved look the penetration of this percent gets targeted population is hi. Maybe future, Should tipifarnib treatable since Thanks to be level ask for penetration is a what questions. high a should understand could very that the us I you for assuming going E into to indication? level? you we the and to what ahead help expect for a an population,

Antonio Gualberto

response line are if I in setting on expecting of standard standard X% rate setting rate, response only are are for care you a that patients those simple be have the no reason say XX% expecting could necessarily not reaching that the we're immediately where high care. certain penetration you of which seeing you a a displacing the are cheap. of immunotherapies, responses, they in And

[indiscernible]. are not displacing You

combination horizontally that is way the monotherapy. in expand those say allele And the can with moving line, the frequency then trying can [indiscernible] maybe But add immunotherapy. on you to which to front I the can settings vertically, expand So, you a best to for not setting. pursue new can all the you

reality those from add of the mutation the being can mechanism carried later tumor with are high the by is then very you appear to combination has or You the the get-go the And that as and because is either XCMAP. driving visions the assistance. frequency

for published. from Hard those progressions At that HRAS. to going think CXCMAP. are RAS of So, mediated. of half They is least be they are those,

the you can of care. resistance to the So, standard delay

do of at you gives that you don't X%-XX% if the So, population selection. least

potential. larger If you it's do directly combination, much obviously,

Jay Olsen

Thanks. of And development? is prioritize very follow-up, identified this will subset in helpful. them? That's with if of these Great. And you you horizon a just then patients apologies But I for as CXCLXX thinking CXCLXX the on potential AACR had biomarker CTCL. Okay. indications how population, and a about DLBCL at benefit maybe expression And are missed the this. clinical

Antonio Gualberto

coming a first reiterate investigators are that So, the been And are and just that that give very to big And this shared number by EHA us excited all, head a of KOL. going has of on lymphoma. ICML. dates in at

[indiscernible] from we The So, enabled going opportunity. gave would us data on this only data the lymphoma. the that thing mycosis

So, sorry.

Just peripheral we that backing been, skin has by original where even T-cell the this lymphoma, been up, he this lesions in that had XXXX. know and shown presented that Wicksett data Tom -- within in

we're five the that that population. So, higher That very in a large large and show more together T-cell obviously the actually more activity medical CTCL. Because a reprocessing But need doubled lymphoma B-cell times also Diffuse cutaneous is lymphoma. T-cell population there's you That There's obviously it's now it's interest. Why? of lymphoma. competition. size.

develop others. But There to opportunity. by still from So, will effectively do we a beachhead lymphoma to companies area with we they do decide we in is going are do that that registration internally just this we very will a targeted we large be discussing Do need and are itself. [indiscernible]. of something

Troy Wilson

to Yes. Jay, proof comments, clear we're Antonio's to these in phase of indications. do concept what very to two demonstrate to trying is add just

head HRAS-mutant neck. with started we and So,

in as being clinical these high-class of of registrations And Rest for accelerated context we're we on only Can a we pathway. of couple You problems. these at couple half mentioned, those highlighting, year. then, And this in And are we the saw indications? tipifarnib presentations laying pursue of monotherapy times it CXCLXX I a meantime, the the a the proof the in the indications. data, to of of June. be in it we're year, that put doing a basket candidate of and, CXCLXX know ways. Antonio our much the both. CMML beachheads drug the doing concept last into groundwork giving different us the larger assured, AITL positive in said back potentially We're obviously, as has ASH

So, that's focus. and out to thoughtful into a what's increasingly we're intermediate-term, be opportunity. near-term, a stake long-term and And coming trying an

Jay Olsen

That's super questions. great. the you my It's for Thank helpful. for Thanks taking details.

Operator

back questions. time, further no remarks. to this call over any turn I'd At to the Troy I'm for closing like showing

Troy Wilson

participating look of the once the week. thank everyone. seeing have in Healthcare you myself. Bank we feel at have Boston tomorrow all next you And Deutsche any many you there. be Pete, today. please Conference to contact and again. the or in if Lynch to Bank meantime, forward additional for Las questions, in good Thank Vegas evening, In the We'll So, of Healthcare you a Conference call Merrill Mark, again America free And

Operator

Ladies your and conclude gentlemen, thank program. does the you in participation This conference. for today's

great day. now may Everyone have disconnect. a You

Kura Oncology (KURA) 7 May 192019 Q1 Earnings call transcript